For over 15 years, Dr Anthony Shum, a pulmonologist at the University of California, San Francisco has been studying a rare genetic disorder called the COPA Syndrome. It stands for coatomer subunit alpha and is a rare, inherited disorder that affects the lungs, joint, and kidney. The National Organization for Rare Disorder also notes that it is a genetic autoimmune disorder that is caused by mutations in the COPA gene. This disease affects families unpredictably—some individuals with the mutation develop severe lung damage early in life, while others remain completely healthy. Now, Shum’s team has discovered a protective genetic variant that may offer new hope for treatment.

A Breakthrough

Researchers found that some relatives of COPA Syndrome patients stayed healthy despite carrying the same COPA gene mutation that causes the disease. The key difference? These unaffected individuals had a protective version of another gene called HAQ-STING.

When scientists introduced HAQ-STING into diseased lung cells from COPA patients, the cells returned to a balanced state, suggesting that this gene could be used as a therapy.

“We really think HAQ-STING could be a gene therapy tool and a step toward a cure,” said Shum, whose findings were published in the Journal of Experimental Medicine.

Families Who Solved The Mystery

Shum’s journey into COPA Syndrome research began in 2011 when he treated a young woman, Letasha, who had severe lung bleeding. Her mother, Betty Towe, mentioned that Letasha’s sister, Kristina, had suffered from similar symptoms. Over the years, Betty had taken both daughters on a four-hour trip to UCSF for treatment. After tracing their family history, Shum discovered that their distant relatives in Texas and Oakland also had lung problems and arthritis. In 2015, Shum, along with scientists from Baylor College of Medicine and Texas Children’s Hospital identified the COPA gene mutation. They realized that it was the common factor behind the illness. However, only some of the 30 individuals with the mutation actually developed symptoms, leaving a major question unanswered.

The Domino Effect

It was established that it occurs when a mutated COPA gene causes another gene STING to go overdrive. The STING that helps fight infections in COPA patients, remain permanently active, which leads to chronic inflammation that damages the lungs, kidneys, and joints. In 2020, while studying STING’s role in the disease, researchers discovered a key variation: HAQ-STING. This version of STING, present in about one-third of the population, appeared to neutralize the harmful effects of the COPA mutation.

To confirm their theory, the scientists needed both affected and unaffected family members to participate in the testing. Letasha, Kristina and Betty immediately volunteered. The researchers then analyzed DNA samples from 26 COPA patients and their healthy relatives. They also conducted CT scans and blood tests to ensure that unaffected members did not have any hidden symptoms. When the findings were all clear, it was revealed that all the healthy individuals had HAQ-STING, while none of the COPA patients did. This was the first known case of a common gene variant completely protecting against a severe genetic disease.

Encouraged by this discovery, researchers tested HAQ-STING’s effects in a lab setting. They introduced it into diseased lung cells from COPA patients, and the cells returned to normal function.

Way Ahead

Shum believes HAQ-STING could lead to game-changing treatments, including:

• Prenatal gene therapy for babies diagnosed with COPA Syndrome before birth
• Aerosol delivery of HAQ-STING for adults, directly targeting the lungs

Before publishing their findings, Shum called Betty with the news—her own HAQ-STING gene had protected her from the disease. He also informed Letasha and Kristina, who were overwhelmed with relief and joy.

“We always believed Dr. Shum would get to the bottom of it,” said Letasha. “This discovery is going to change lives.”

Hepatitis remains one of the most misunderstood liver conditions, largely because it isn't a single disease but a group of infections—A, B, C, D, and E—each of which behaves very differently once it enters the body.

The question "can hepatitis be cured?" doesn't have one straightforward answer. The truth lies somewhere between full recovery and lifelong management, depending entirely on which type of hepatitis a person has contracted.

Not All Hepatitis Is the Same

Hepatitis A and E are generally short-lived infections. The liver, in most cases, clears these viruses naturally without any specific antiviral medication. Rest, hydration, a balanced diet, and avoiding alcohol are usually enough to help the body recover fully. Chronic infection is rare with these two types, and when it does occur, particularly with Hepatitis E in people with weakened immunity, it can still be treated successfully.

Hepatitis C tells a much more encouraging story. Thanks to advances in medicine, Direct-Acting Antivirals, or DAAs, now cure more than 95 percent of cases. These are oral tablets taken for roughly eight to twelve weeks, and they carry minimal side effects compared to older treatments. For patients diagnosed early, Hepatitis C is, quite genuinely, curable.

Where Treatment Manages Rather Than Cures

Hepatitis B and D are a different story altogether. When the infection is acute, the body often fights it off on its own without much trouble.

Chronic cases, though, are far tougher to deal with. As of now, no medication can fully remove the Hepatitis B virus from the body once it settles in. What doctors can do is keep it under control, usually through antiviral tablets or interferon injections, so that it doesn't quietly damage the liver over time and lead to cirrhosis or cancer. For many patients, this isn't a short course of treatment. It's something they may need to stay on for years, and in several cases, for the rest of their lives.

Hepatitis D is considered the more severe of the two, and it only shows up in people who already have Hepatitis B; it cannot infect someone on its own. Treatment choices here are still quite limited. A few newer drugs have shown some promise in keeping the disease in check, but nothing yet counts as an actual cure. When the liver damage has progressed too far, a transplant sometimes becomes the only way forward.

Why Early Diagnosis Changes The Outcome

The single most important factor in determining outcomes across all types of hepatitis is timing. Detected early, Hepatitis C can be eliminated. Detected early, Hepatitis B can be controlled well enough that liver damage never progresses. Left unchecked, however, both can silently damage liver tissue for years before symptoms even appear.

Regular liver function tests, hepatitis screening for those at risk, and vaccination—especially for Hepatitis B—remain the strongest tools available for prevention and timely intervention.

The Bottom Line

Hepatitis doesn't follow a single script, and that's something patients often find confusing at first. Some forms clear up completely with the right treatment, others require ongoing management to keep the virus in check, and in many cases, vaccination and timely screening make the real difference in avoiding complications down the line.

Knowing exactly which type of hepatitis one is dealing with is what allows a doctor and patient to set realistic expectations and work out a treatment plan that actually fits the situation.

The rise of GLP-1 medications such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide) has transformed obesity and diabetes treatment.

However, soaring demand and earlier drug shortages also fueled the rapid growth of compounded GLP-1 drugs, which are now under increasing scrutiny from regulators and medical experts.

Over the past few months, the U.S. Food and Drug Administration (FDA) has intensified its crackdown on compounded GLP-1 products, warning that patients could face quality, dosing, and safety concerns if they obtain these medications from unlawful sources.

What Are Compounded GLP-1 Drugs?

A compounded drug is a medication that is custom-made by a licensed compounding pharmacy to meet an individual patient's specific medical needs. For example, removing an allergen, changing the dosage, or preparing a formulation that is not commercially available.

The FDA said, "Compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed."

Also read: People Are Microdosing GLP-1 Weight Loss Drugs; What Do Experts Have To Say About It?

Why Have Compounded GLP-1 Drugs Become Popular?

Demand for GLP-1 medications for weight loss skyrocketed worldwide between 2022 and 2025, leading to shortages of semaglutide and tirzepatide.

During these shortages, compounding pharmacies were legally allowed under specific circumstances to prepare several versions of these medications.

Many patients turned to compounded GLP-1s because they were often affordable, available, and easier to buy online.

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

FDA Is Tightening Scrutiny

FDA's efforts to restrict this practice include widespread compounding of semaglutide, tirzepatide, and liraglutide.

The agency has proposed excluding these drugs from the list of bulk substances used for large-scale compounding because FDA-approved alternatives are now available.

It has also issued warning letters to companies producing compounded GLP-1 products outside permitted circumstances.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

Recent Research Raises New Concerns

A new University of Colorado Anschutz Medical Campus secret shopper study published in July 2026 found that the compounded GLP-1 market remains active even after shortages have been curbed.

Researchers reported that many online pharmacies were still selling compounded semaglutide or tirzepatide, with some products originating from pharmacies lacking compounding licenses.

Potential Risks of Compounded GLP-1 Drugs

Inaccurate Dosing

Small differences in concentration may result in patients receiving too much or too little medication.

Sterility Concerns

Injectable medicines must be manufactured under strict sterile conditions. Improper preparation increases the risk of contamination.

Different Ingredients

Some compounded products have reportedly used semaglutide salts or added vitamins and other substances that are not present in FDA-approved versions. The FDA has previously stated that certain semaglutide salt forms have not been demonstrated to be safe or effective.

Limited Safety Data

Because compounded products are not FDA-approved, they have not undergone the rigorous clinical trials evaluating effectiveness, manufacturing consistency, and long-term safety.

Counterfeit or Unregulated Products

Experts warn that some websites advertise compounded GLP-1 medications that may not come from legitimate pharmacies at all.

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.

Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.

However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.

What Is GLP-1 Microdosing?

Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.

HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.

Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.

The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."

Why Are People Trying It?

Fewer Side Effects

Lower Cost

These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.

Weight Maintenance

Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.

Longevity Claims

Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

The Risks of Microdosing

Reduced Effectiveness

Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.

Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."

Delayed Medical Treatment Or Risk Of Expiration

Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.

Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."

Inaccurate Dosing

Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So

Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.

The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."